

JOURNAL-BASED LEARNING EXERCISES



Please select your choice of correct answers and complete the exercises online at: www.ibms.org/cpd/jbl

DEADLINE WEDNESDAY 8 JANUARY 2020

The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban Kim B, Jang S, Lee YJ, Park N, Cho YU, Park CJ. <i>Br J Biomed Sci</i> 2019; 76 (3): 122–8. Assessment No: BJBS1019A		Genetic polymorphisms in DNA repair genes and their association with cervical cancer Abbas M, Srivastava K, Imran M, Banerjee M. <i>Br J Biomed Sci</i> 2019; 76 (3): 117–21. Assessment No: BJBS1019B	
01	Anticoagulants such as warfarin and heparin are widely used to treat venous thromboembolism, and do not require frequent monitoring to ensure correct plasma levels.	01	Carcinoma of cervix is the third most common cancer among women worldwide, with approximately 530,000 new cases and 275,000 deaths each year.
02	Prothrombin time is not a good candidate for a method to measure the plasma concentration of rivaroxaban.	02	Epidemiologic studies have shown that most cases of cervical cancer are caused by the human papillomavirus (HPV), mainly HPV-16 and HPV-18.
03	Rivaroxaban is a widely used direct inhibitor of activated factor X (Xa).	03	Among various DNA repair pathways, base excision repair (BER) restores DNA double-strand breaks.
04	The study cohort comprised 337 healthy individuals (157 males, 180 females).	04	Genetic polymorphisms in DNA repair genes may be associated with repair efficiency of damaged DNA and influence cancer risk.
05	Rivaroxaban (50 mg) was dissolved in 20 mL dimethylsulphoxide (DMSO) to produce a stock solution diluted in phosphate-buffered saline without Ca ²⁺ or Mg ²⁺ at a final rivaroxaban concentration of 500 mg/mL.	05	The Arg188His polymorphism of <i>XRCC1</i> plays an important role in pancreatic and colorectal carcinogenesis.
06	A total of 60 rivaroxaban-spiked plasma samples were analysed.	06	Cervical cancer patients (n=230) and healthy age-matched controls (n=270) aged between 30 and 70 years were recruited for the study.
07	To evaluate sensitivity variations among different thromboplastins, plots were drawn for the spiked concentration of rivaroxaban and PT of each sample.	07	Frozen EDTA blood samples were thawed at room temperature and high molecular weight DNA was extracted using a slightly modified salting out method.
08	Three chromogenic anti-factor Xa assay reagents were used in this study.	08	The sample size for each SNP was calculated by QUANTO software using major allele frequency and prevalence.
09	Specific rivaroxaban anti-factor Xa activity was measured using two different instruments.	09	Of the cervical cancer cases, 93.5% were in stages II/III with 6.5% in stages I/IV.
10	All three thromboplastins tested showed the same sensitivity to rivaroxaban.	10	Compared to the GG genotype, adjusted frequencies of GA, AA and GA+AA genotypes were lower in cases compared to controls.
11	The mean (SD) for warfarin-adjusted INR using Neoplastin CI-plus was 1.80 (0.97).	11	Digested products were visualised on 2% polyacrylamide gel after staining with ethidium bromide.
12	Rivaroxaban-adjusted SI values were different from the current warfarin-adjusted ISI in all tested thromboplastins.	12	Cervical cancer is a complex disease where environmental and genetic factors play important roles in pathogenesis.
13	Rivaroxaban-specific NR does not reduce the differences between the PT results from different thromboplastins and coagulometers.	13	Women with GA and AA genotypes of <i>XRCC1+399A/G</i> showed 2.8–3.4-fold higher risk of cervical cancer.
14	HemoSIL Recombiplastin 2G originates from a human source, so this thromboplastin represents the WHO calibration method.	14	The raw carriage rates of G (+), G (–) and A (+), A (–) showed significant association with cervical cancer when compared to controls.
15	Studies have shown a poor correlation between the anti-factor Xa assay and mass spectrometric measurement of rivaroxaban in normal plasma samples spiked with known amounts of rivaroxaban.	15	Amplification was followed by initial denaturation at 95°C, followed by 35 cycles at 95°C, annealing at 56°C, extension at 72°C, and final extension at 72°C.
16	The authors found that use of a rivaroxaban-adjusted NR did not minimise inter-thromboplastin variability.	16	The <i>XRCC3+18067C/T</i> genetic variant is associated with cervical cancer.
17	Traditional coagulation tests are speedy, widely available and inexpensive, and are suitable for determining plasma DOAC levels.	17	The important molecules of the BER pathway are RAD51, <i>XRCC2</i> and <i>XRCC3</i> .
18	Spiked samples reflect the potential variations of sensitivity between thromboplastins and between <i>in vivo</i> samples with similar levels of rivaroxaban.	18	In the study population, the frequency of GA and AA genotypes, and the A allele of <i>XRCC1+399A/G</i> are significantly lower in cases compared to controls.
19	Mass spectrometry, the current validated standard, was not used to measure plasma rivaroxaban concentration.	19	Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism.
20	Anti-Xa assay versus NR-rivaroxaban correlation coefficients were 0.97–0.99.	20	The major allele frequency was calculated after genotyping 100 normal individuals for each SNP.
REFLECTIVE LEARNING			
01	In certain circumstances, monitoring of plasma rivaroxaban concentration might be needed. Discuss.	01	Molecular genetics is set to play an increasing and important role in cytopathology. Discuss.
02	Explain in detail why this paper by Kim <i>et al.</i> represents an advance in biomedical science.	02	Explain in detail why this paper by Abbas <i>et al.</i> represents an advance in biomedical science.